First Analysis Weighs in on Cambrex Co.’s Q3 2018 Earnings (CBM)

Cambrex Co. (NYSE:CBM) – Research analysts at First Analysis boosted their Q3 2018 EPS estimates for shares of Cambrex in a research report issued on Monday. First Analysis analyst S. Schwartz now expects that the biotechnology company will earn $0.57 per share for the quarter, up from their previous forecast of $0.56.

Cambrex (NYSE:CBM) last released its earnings results on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.17. The company had revenue of $182.28 million during the quarter, compared to the consensus estimate of $181.39 million. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. Cambrex’s revenue was up 2.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.23 EPS.

Several other equities analysts also recently weighed in on CBM. Craig Hallum reaffirmed a “buy” rating and issued a $60.00 target price (down from $70.00) on shares of Cambrex in a research report on Tuesday, October 31st. Zacks Investment Research raised Cambrex from a “strong sell” rating to a “hold” rating in a research report on Monday, January 15th. Finally, William Blair began coverage on Cambrex in a research report on Tuesday, January 16th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. Cambrex presently has a consensus rating of “Hold” and a consensus target price of $60.00.

Cambrex (NYSE CBM) traded down $0.35 during midday trading on Tuesday, reaching $52.85. The company’s stock had a trading volume of 18,332 shares, compared to its average volume of 374,404. The firm has a market cap of $1,701.46, a P/E ratio of 17.33, a P/E/G ratio of 1.21 and a beta of 2.38. Cambrex has a 52 week low of $42.55 and a 52 week high of $62.95.

Several institutional investors have recently made changes to their positions in CBM. Northern Trust Corp grew its position in shares of Cambrex by 3.7% during the second quarter. Northern Trust Corp now owns 566,302 shares of the biotechnology company’s stock worth $33,837,000 after buying an additional 19,955 shares in the last quarter. California Public Employees Retirement System grew its position in shares of Cambrex by 4.4% during the second quarter. California Public Employees Retirement System now owns 73,500 shares of the biotechnology company’s stock worth $4,392,000 after buying an additional 3,100 shares in the last quarter. Advisor Group Inc. grew its position in shares of Cambrex by 29.8% during the second quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock worth $160,000 after buying an additional 615 shares in the last quarter. Parametric Portfolio Associates LLC grew its position in shares of Cambrex by 5.4% during the second quarter. Parametric Portfolio Associates LLC now owns 93,817 shares of the biotechnology company’s stock worth $5,606,000 after buying an additional 4,841 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Cambrex by 32.5% during the second quarter. Renaissance Technologies LLC now owns 254,202 shares of the biotechnology company’s stock worth $15,189,000 after buying an additional 62,402 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “First Analysis Weighs in on Cambrex Co.’s Q3 2018 Earnings (CBM)” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/02/13/first-analysis-weighs-in-on-cambrex-co-s-q3-2018-earnings-cbm.html.

Cambrex Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply